hotspot -WSS

hotspot

author：comprehensive 2025-09-28 22:53:05 - browse：14361

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Opioid cravings were reduced by anti

entertainment

WSS

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Tome Biosciences co

Flagship Pioneering startup Sonata Therapeutics lays off 21

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Elevance, SCAN deals highlight health insurer acquisition scrutiny

hotspot

hotspot

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Medicare proposal to cover medical devices draws a mixed reaction

Doctors on social media are being harassed and cyberbullied

Alkermes shareholders re

Why Eli Lilly’s earnings didn’t quite live up to the hype

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

In age of alternative facts, a scholarly course on calling out crap

Abridge raises $150m as clinical notes automation market heats up

hotspot

AMAs digital advisors table RPM coding reform proposal, again

Abbott's new heart device gets FDA advisory panel nod

Long Covid research funding gets a major boost from NIH

Measles policy set amid Florida outbreak alarms vaccine proponents

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Weight loss drugs aren’t covered by Obamacare. That may change

knowledge

entertainment

entertainment

hotspot